Article
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Cancer - 15 Apr 2014
Reckamp Karen L, Giaccone Giuseppe, Camidge D Ross, Gadgeel Shirish M, Khuri Fadlo R, Engelman Jeff A, Koczywas Marianna, Rajan Arun, Campbell Alicyn K, Gernhardt Diana, Ruiz-Garcia Ana, Letrent Stephen, Liang Jane, Taylor Ian, O'Connell Joseph P, Jänne Pasi A
Abstract excerpt
BACKGROUND: This phase 2 trial (ClinicalTrials.gov identifier NCT00548093) assessed the efficacy, safety, and impact on health-related quality of life of dacomitinib (PF-00299804), an irreversible tyrosine kinase inhibitor (TKI) of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HE...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.